Posted on by Pencis
73 / 100
Powered by Rank Math SEO
SEO Score

Assoc. Prof. Dr. Nah Hao | Cancer | Best Researcher Award

The first Hospital Affiliated to Xi’an Jiaotong University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Assoc. Prof. Dr. Na Hao began her medical journey at Nankai University School of Medicine, where she earned her Bachelor’s degree in Clinical Medicine (2008–2013), followed by a Master of Medicine in Surgery (2013–2015). Her early research delved into breast cancer biology, including clinical diagnostics and imaging techniques such as MRI. She went on to pursue a Ph.D. in Oncology (2015–2019) at the same institution, exploring tumor microenvironment, cancer stemness, and chemotherapy resistance, laying a strong foundation for her future breakthroughs.

💼PROFESSIONAL ENDEAVORS

Since June 2019, Dr. Na Hao has served as an Attending Surgeon and Associate Professor at The First Hospital Affiliated to Xi’an Jiaotong University. Combining clinical precision with scientific inquiry, she operates on the front lines of breast cancer treatment while leading pioneering cancer research. Her dual role as clinician and academic reflects a rare blend of medical excellence and intellectual leadership.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER

Dr. Hao’s research is highly translational, targeting some of the most pressing challenges in oncology, including:

  1. Tumor angiogenesis and immunotherapy resistance, crucial for understanding tumor progression and treatment failure.

  2. Endocrine and chemotherapy resistance in breast cancer, particularly HR+ and triple-negative breast cancer (TNBC).

  3. Molecular signaling pathways, including PI3K mutations, ROS oxidative stress, and the role of AHNAK2 and PDE3A in cancer survival mechanisms.

Her research emphasizes the importance of precision medicine, with a focus on biomarkers such as CTCs (Circulating Tumor Cells) and ctDNA.

🌍IMPACT AND INFLUENCE

  • Public Health Education Ambassador for breast health awareness across 16 cities in China, promoting early detection and prevention.

  • International presenter at premier conferences such as the American Association for Cancer Research (AACR) and World Cancer Congress.

  • A textbook contributor to Parathyroidology, bridging the gap between clinical knowledge and student education.

  • Influential figure in the Chinese Society of Breast Prevention, contributing to national standards and outreach efforts.

🏆RESEARCH GRANTS AND FUNDING

Dr. Hao has successfully secured prestigious national and provincial grants as Principal Investigator, including:

  1. 2020–2023 – PDE3A-mediated endocrine resistance in HR+ breast cancer
    National Natural Science Foundation of China (NSFC) – Grant No. 8-2003183

  2. 2022–2024 – AHNAK2’s role in chemotherapy resistance via ROS modulation in TNBC
    Key R&D Program, Shanxi Province – Grant No. 2022SF-080

🦠LEGACY AND FUTURE CONTRIBUTIONS

  • Her patented invention of a low-temperature plasma surgical device (CN1041611584A) reflects her forward-thinking in surgical oncology.

  • Her current and future work focuses on overcoming resistance in breast cancer treatments, aiming to develop personalized therapies for improved patient outcomes.

  • As an educator, public speaker, and surgical expert, she is mentoring the next generation of oncologists and researchers.

🌟A VISIONARY IN INFECTIOUS DISEASES

Though primarily focused on cancer, Dr. Hao’s expertise in tumor microenvironments and immune resistance contributes to broader understandings in infectious diseases and immunopathology. Her cross-disciplinary insights are crucial for developing immunotherapy strategies that can be translated beyond oncology.

📑NOTABLE PUBLICATIONS

The role of magnetic resonance imaging in detection and surgical treatment of breast intraductal papillomas

Authors: Na Hao, Xiaoyan Yuan, Quansheng Wang, Junyong Zhu, Yiqiong Zheng, Yanjun Zhang, Mei Liu, Liuquan Cheng, Xiru Li​

Publication Year: 2019​

Journal: Translational Cancer Research​

 TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways

Authors: Wenzhi Shen, Renle Du, Jun Li, Xiaohe Luo, Shaorong Zhao, Antao Chang, Wei Zhou, Ruifang Gao, Dehong Luo, Juan Wang, Na Hao, Yanhua Liu, Yanan Chen, Yunping Luo, Peiqing Sun, Shuang Yang, Na Luo, Rong Xiang

Publication Year: 2016

Journal: Signal Transduction and Targeted Therapy​

ICAM3 mediates inflammatory signaling to promote cancer cell stemness

Authors: Wenzhi Shen, Junling Xie, Shaorong Zhao, Renle Du, Xiaohe Luo, Shan Jiang, Na Hao, Chong Chen, Chonglei Guo, Yanhua Liu, Yanan Chen, Peiqing Sun, Shuang Yang, Na Luo, Rong Xiang, Yunping Luo​

Publication Year: 2018​

Journal: Cancer Letters

Assoc. Prof. Dr. Nah Hao | Cancer | Best Researcher Award

You May Also Like